Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer

Pfizer’s breast cancer drug Ibrance is under increased pressure from rival CDK4/6 inhibitors from Novartis and Eli Lilly thanks to a couple of big clinical slips. And in the wake of those misses, Pfizer has turned to real-world data for support.